Senior Principal Scientist Genentech, Inc. South San Francisco, California, United States
This presentation will focus on safety study considerations for the intravitreal delivery of peptides, a less used route of administration for this therapeutic modality. Case studies will be presented, highlighting differences from current guidance documents and the challenges with intravitreal delivery compared with the more common routes of subcutaneous and intravenous injection.
